/ /

  • linkedin
  • Increase Font
  • Sharebar

    FDA approves one-of-a-kind IOL with extended range of vision

    It has been a history-making week for the ophthalmic world, and the FDA approval of the first IOL with extended range of vision (Tecnis Symfony IOL, Abbott) has only added one more reason for celebration.

    The novel IOL is the only lens of its kind to be approved in the United States for providing continuous extended-depth-of-focus and visual acuity (VA) following cataract surgery, according to the company. The lens also reduces presbyopia effects by giving patients near vision, while having halos and glare incidence rates that are comparable to a monofocal IOL, the company reported.  

    The FDA approval also includes a toric version of the lens for patients with astigmatism. 

    News: FDA approves Shire's dry eye drug

    Numerous clinical studies including more than 2,000 eyes have explored the capabilities of the novel lens which has been approved in over 50 countries. The studies have shown that the lens provided continuous, sharp vision at near, intermediate, and distance, and at points in between.

    “What makes it so special is that it is a much more forgiving lens,” said Eric D. Donnenfeld, MD, Ophthalmic Consultants of Long Island, New York, investigator for the clinical trial.

    Sponsored: Going to be in San Francisco August, 2016? Join us for dinner!

    Dr. Donnenfeld recalled a situation from the trial that he had not experienced in his career. After the cataract surgeries were performed on the control and treatment groups, the patients were placed into a single waiting room.

    Soon after, one of the control patients realized she could not read at near distance. She became so upset, she insisted the monofocal lens be removed and that she be implanted with the extended-depth-of-focus IOL.

    Related: Does femto laser or manual cataract removal have better accommodating IOL outcomes?

    “It was the first time in my experience where a patient had a control lens and wanted the experimental lens,” Dr. Donnenfeld said. (After 90 days, the patient’s request was granted.)

    “In 2016, patients don’t read as much as they used to at reading distances of 20 inches or so,” he said, adding that daily life today revolves around mid-range vision with cellphones and computer screens. “So it’s the perfect lens for someone who has a lifestyle that revolves around being about to see at mid-range…which is just about everybody.” 

    Recent: ARVO 2016 meeting paves path for personalized medicine

    Technology behind the design

    Jolie Higazi
    Jolie is the Content Specialist for Ophthalmology Times. She can be reached at jolie.higazi@advanstar.com.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results